Evidence map›Paper›PMID 32336655›Full record

ArticleAnnals of epidemiology2020

Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018.

Aaron J Siegler, C Christina Mehta, Farah Mouhanna, Robertino Mera Giler, Amanda Castel, Elizabeth Pembleton, Chandni Jaggi, Jeb Jones, Michael R Kramer, Pema McGuinness and 2 more

Abstract read
In one paragraph

Article in Annals of epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The prevalence of HIV pre-exposure prophylaxis (HIV-PrEP) use and HIV-PrEP-to-need ratio in nine Canadian provinces, 2018-2021.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aaron J SieglerDepartment of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, Atlanta, GA. Electronic address: asiegle@emory.edu.
C Christina MehtaDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA.
Farah MouhannaDepartment of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, Atlanta, GA; Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC.
Robertino Mera GilerDepartment of Epidemiology, Gilead Sciences, Foster City, CA, 94404.
Amanda CastelDepartment of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC.
Elizabeth PembletonDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Chandni JaggiDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Jeb JonesDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Michael R KramerDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Pema McGuinnessDepartment of Epidemiology, Gilead Sciences, Foster City, CA, 94404.
Scott McCallisterDepartment of Epidemiology, Gilead Sciences, Foster City, CA, 94404.
Patrick S SullivanDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
The UNC/Emory Center for Innovative Technology (iTech) across the prevention and care continuumU19HD089881 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HIGHTOW-WEIDMAN, LISA B, SULLIVAN, PATRICK SEAN · 2016 to 2022
$35.8M
Population-based survey of SARS-CoV-2 infection and immune responseR01AI143875 · NIAID · EMORY UNIVERSITY · PI SIEGLER, AARON JULIUS, SULLIVAN, PATRICK SEAN · 2019 to 2023
$9.2M
Making it last: A randomized, controlled trial of a home care system to promote persistence in PrEP careR01MH114692 · NIMH · EMORY UNIVERSITY · PI MAYER, KENNETH H, SIEGLER, AARON JULIUS · 2017 to 2021
$5.8M
NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI143875NICHD NIH HHS U19 HD089881NIMH NIH HHS R01 MH114692
6 · The paper itself

Abstract

purposeHIV pre-exposure prophylaxis (PrEP) is highly efficacious, and yet most individuals indicated for it are not currently using it. To provide guidance for health policymakers, researchers, and community advocates, we developed county-level PrEP use estimates and assessed locality and policy associations.

methodsUsing data from a national aggregator, we applied a validated crosswalk procedure to generate county-level estimates of PrEP users in 2018. A multilevel Poisson regression explored associations between PrEP use and (1) state policy variables of Medicaid expansion and state Drug Assistance Programs (PrEP-DAPs) and (2) county-level characteristics from the U.S. Census Bureau. Outcomes were PrEP per population (prevalence) and PrEP-to-need ratio (PnR), defined as the ratio of PrEP users per new HIV diagnosis. Higher levels of PrEP prevalence or PnR indicate more PrEP users relative to the total population or estimated need, respectively.

resultsOur 2018 county-level data set included a total of 188,546 PrEP users in the United States. Nationally, PrEP prevalence was 70.3/100,000 population and PnR was 4.9. In an adjusted model, counties with a 5% higher proportion of black residents had 5% lower PnR (rate ratio (RR): 0.95, 95% confidence interval (CI): 0.93, 0.96). Similarly, counties with higher concentration of residents uninsured or living in poverty had lower PnR. Relative to states without Medicaid expansion or PrEP-DAPs, states with only one of those programs had 25% higher PrEP prevalence (RR: 1.25, 95% CI: 1.09, 1.45), and states with both programs had 99% higher PrEP prevalence (RR: 1.99, 95% CI: 1.60, 2.48). There was a significant linear trend across the three policy groups, and similar findings for the relation between PnR and the policy groups.

conclusionsIn a data set comprising approximately 80% of PrEP users in the United States, we found that Medicaid expansion and PrEP-DAPs were associated with higher PrEP use in states that adopted those policies, after controlling for potential confounders. Future research should identify which components of PrEP support programs have the most success and how to best promote PrEP among groups most impacted by the epidemic. States should support the admirable health decisions of their residents to get on PrEP by implementing policies that facilitate access.

Indexed as

Policy MakingAdultAgedAnti-HIV AgentsFemaleHealth PolicyHIV InfectionsHumansLocal GovernmentMaleMedicaidMiddle AgedPre-Exposure ProphylaxisResidence CharacteristicsUnited StatesAnti-HIV AgentsHIVPre-exposure prophylaxisPrevention

Identifiers

PMID32336655
PMCPMC7246022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.